Biohaven

Biohaven

A modern pharmaceutical company guided by science and inspired to change the lives of people with unmet medical needs.

Founded 2022

New Haven, United States 447 employees Post-IPO Equity Total: $1.44B Biotechnology, Health Care +1

Biohaven is a modern pharmaceutical company guided by science and inspired to change the lives of people with unmet medical needs. The company prides itself on being uniquely different, with an agile and resilient team of highly skilled professionals who eagerly challenge the status quo to advance novel, life-changing therapies. Biohaven places people at the center of all its operations, drawing inspiration from the unmet needs of patients to drive scientific innovation and resolve obstacles in the way of medical progress. This patient-first culture is embodied in the "Biohaven Way." Founded in 2022 and headquartered in the United States, Biohaven recently received a significant $230.00MPost-IPO Equity investment on 18 April 2024. The company operates in the Biopharma, Biotechnology, and Health Care industries, emphasizing its commitment to addressing unmet medical needs. For those interested in career opportunities at Biohaven, the company provides information on its Careers page. Investors can find news and financial information about Biohaven (NYSE: BHVN) on the Investor Relations page. An overview of Biohaven's pipeline can also be accessed on the company's Pipeline page.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Equity	$230.00M	-		18 Apr 2024
Post IPO Equity	$10.00M	1	HighlightLL Pharma	22 Mar 2023
Post IPO Equity	$301.90M	-		20 Oct 2022
Post IPO Equity	Undisclosed	1	Soros Fund Management	30 Jun 2022
Post IPO Equity	$200.00M	-		15 Mar 2021
Post IPO Equity	$450.00M	1	Royalty Pharma	07 Aug 2020
Post IPO Equity	$143.70M	-		17 Dec 2018
Venture Round	$20.00M	-		07 Mar 2017
Venture Round	$80.00M	10	Connecticut Innovations, RA Capital Management +8	01 Nov 2016

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Equity

$230.00M

18 Apr 2024

Post IPO Equity

$10.00M

HighlightLL Pharma

22 Mar 2023

Post IPO Equity

$301.90M

20 Oct 2022

Post IPO Equity

Undisclosed

Soros Fund Management

30 Jun 2022

Post IPO Equity

$200.00M

15 Mar 2021

Post IPO Equity

$450.00M

Royalty Pharma

07 Aug 2020

Post IPO Equity

$143.70M

17 Dec 2018

Venture Round

$20.00M

07 Mar 2017

Venture Round

$80.00M

Connecticut Innovations, RA Capital Management +8

01 Nov 2016

FAQ About Biohaven

A modern pharmaceutical company guided by science and inspired to change the lives of people with unmet medical needs.

Biohaven was founded in 2022.

Biohaven is headquartered in New Haven, United States.

Biohaven operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on pharmaceutical, medical innovation, patient-first and clinical development.

Biohaven has approximately 447 employees.

Biohaven has completed 9 funding rounds, raising a total of $1.44B. The latest funding stage is Post-IPO Equity.

Top alternatives and competitors to Biohaven include Gossamer Bio, Day One Biopharmaceuticals, Helioson, Merck & Co., Inc., PMG Research. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Biohaven and Gossamer Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Biohaven

Funding Rounds & Investors (9)

Biohaven Alternatives & Competitors

FAQ About Biohaven